Literature DB >> 19373561

How the conflict between American psychiatry and neurology delayed the appreciation of cognitive dysfunction in multiple sclerosis.

Michelle A Butler1, John R Corboy, Christopher M Filley.   

Abstract

Whereas cognitive deficits in multiple sclerosis (MS) were documented in the original clinicopathological description by Charcot, the extent and nature of cognitive dysfunction was poorly understood in the U.S. until over a century later. Our objective was to discern reasons for this misunderstanding and to examine forces shifting this topic to center stage of research and increased awareness in clinical practice. We hypothesized that during the 19th century, conflict between psychiatrists and neurologists over control of treatment of the mentally ill fueled a misunderstanding of the nature of MS which led neurologists to treat diseases of the body, and psychiatrists, diseases of the mind. The importance of cognitive deficits in MS was thus minimized until scientific breakthroughs could once again bring them to light. As the rift between disciplines peaked, awareness of cognitive deficits diminished, and vice versa. This may have been one contributing factor affecting how MS was mistakenly conceptualized for a century.

Entities:  

Mesh:

Year:  2009        PMID: 19373561     DOI: 10.1007/s11065-009-9089-y

Source DB:  PubMed          Journal:  Neuropsychol Rev        ISSN: 1040-7308            Impact factor:   7.444


  35 in total

1.  The wall between neurology and psychiatry.

Authors:  Mary G Baker; Rajendra Kale; Matthew Menken
Journal:  BMJ       Date:  2002-06-22

2.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

3.  A happy state of mind: a history of mild elation, denial of disability, optimism, and laughing in multiple sclerosis.

Authors:  S Finger
Journal:  Arch Neurol       Date:  1998-02

4.  The persistence of mind-brain dualism in psychiatric reasoning about clinical scenarios.

Authors:  Marc J Miresco; Laurence J Kirmayer
Journal:  Am J Psychiatry       Date:  2006-05       Impact factor: 18.112

5.  Studies on the natural history of multiple sclerosis. 6. Clinical and laboratory findings at first diagnosis.

Authors:  J F Kurtzke; G W Beebe; B Nagler; T L Auth; L T Kurland; M D Nefzger
Journal:  Acta Neurol Scand       Date:  1972       Impact factor: 3.209

6.  Neuropsychological test performance as a function of the duration of MS-related symptomatology.

Authors:  R J Ivnik
Journal:  J Clin Psychiatry       Date:  1978-04       Impact factor: 4.384

7.  Caring for the chronically mentally ill.

Authors:  R L Martensen
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

8.  Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis.

Authors:  G Comi; M Filippi; V Martinelli; G Sirabian; A Visciani; A Campi; S Mammi; M Rovaris; N Canal
Journal:  J Neurol Sci       Date:  1993-04       Impact factor: 3.181

9.  Cognitive function in patients with multiple sclerosis.

Authors:  J M Peyser; K R Edwards; C M Poser; S B Filskov
Journal:  Arch Neurol       Date:  1980-09

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  2 in total

Review 1.  Neuroimaging biomarkers in mild traumatic brain injury (mTBI).

Authors:  Erin D Bigler
Journal:  Neuropsychol Rev       Date:  2013-08-24       Impact factor: 7.444

2.  Neuroimaging distinction between neurological and psychiatric disorders.

Authors:  Nicolas A Crossley; Jessica Scott; Ian Ellison-Wright; Andrea Mechelli
Journal:  Br J Psychiatry       Date:  2015-06-04       Impact factor: 9.319

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.